Company-wide revenue
Reported revenue in 2021 ¥1.04T Reported revenue in 2025 ¥2.12T
- growth amount
- +¥1.08T
- growth annualized
- +19.4%
- growth total
- +103.2%
Japanese company profile · 4568
DAIICHI SANKYO COMPANY, LIMITED
In its FY2025 public filing, DAIICHI SANKYO COMPANY, LIMITED reports Pharmaceuticals. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 第一三共株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
DAIICHI SANKYO COMPANY, LIMITED's largest reported business by revenue in FY2025 was Pharmaceuticals.
The business with the highest reported segment profit in FY2025 was Pharmaceuticals.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Pharmaceuticals
- 医薬品事業
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Pharmaceuticals
- 医薬品事業
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Reported Segment revenue by business over time
Reported Segment revenue by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Pharmaceuticals | ¥1.04T | ¥1.28T | ¥1.6T | ¥1.89T | ¥2.12T |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Pharmaceuticals
Reported revenue in 2021 ¥1.04T Reported revenue in 2025 ¥2.12T
- growth amount
- +¥1.08T
- growth annualized
- +19.4%
- growth total
- +103.2%
View original filing
Pharmaceuticals
Reported profit margin in 2022 +9.4%
Reported profit margin in 2025 +10.8%
- growth margin points
- +1.4
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YEY0
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.